BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Following the success of the first-ever instalment of the Sarona Kalahari 1000 Race, the Botswana Motor Sport (BMS) is open to hosting more races of this magnitude.